Clinical trial · Observational
Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients
Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients (ECHO)
NCT03062072CI-TRIAL-00026868ECHOunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess chemotherapy related hyperglycemia in non-diabetic patients, the investigators will assess the incidence of hyperglycemia and analyze co-medications and risk factors.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Malignant Lymphoma | Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Incidence of type 2 diabetes mellitus
- timeFrame
- during chemotherapy (about 1 year)
- description
- Percentage of patients who progressed to type 2 diabetes
Secondary outcomes (3)
- measure
- Change in HbA1c
- timeFrame
- during chemotherapy (about 1 year)
- measure
- Change in glycated albumin
- timeFrame
- during chemotherapy (about 1 year)
- measure
- Recurrence free survival (RFS)
- timeFrame
- from the Date of enrollment to the date of disease recurrence or date of any cause assessed upto 100 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with cancers (colorectal, breast) who treated with curative intents and ones with malignant lymphoma who are expected to achieve complete remission with chemotherapy (mainly, CHOP regimen) * Patients without history of diabetes mellitus * Normal glucose tolerance, as defined in the protocol Exclusion Criteria: * Patients with diabetes mellitus or hyperglycemia, as defined in the protocol
References
Publications (1)
- DERIVEDLee EK, Koo B, Hwangbo Y, Lee YJ, Baek JY, Cha YJ, Kim SY, Sim SH, Lee KS, Park IH, Lee H, Joo J, Go S, Heo SC, Moon MK. Incidence and disease course of new-onset diabetes mellitus in breast and colorectal cancer patients undergoing chemotherapy: A prospective multicenter cohort study. Diabetes Res Clin Pract. 2021 Apr;174:108751. doi: 10.1016/j.diabres.2021.108751. Epub 2021 Mar 17. PMID 33722701